RE:RE:RE:RE:RE:Spectral Sale StrategyAccountprince wrote: MM you are correct that nothing is adding up. A company has massive scientific achievements over a couple of years with the last two items (admittedly major ones) progressing very positively. This company has extended the time frame for use of technology agreements for PMX (Toray) and SAMI and DIMI (Infomed) and has a major pharma company on board with Baxter. They have the leading industry expert on board as the CMO. There is an investment analyst (Paradigm) with a valuation for the company well in excess of the current trading price. Everything is pointing to a once in a decade home run of biblical proportions.
The complaints seem to be centred on the CFO then promoted to COO and then promoted to CEO and now given a board seat. Under his management the share price that was thought to be set to move up to several dollars per share a couple of years ago has fallen to new lows and closed today at $0.22 per share. He authored two share offerings at $0.60 (incl warrants) per share and $0.425 (incl warrants) per share. It seems all operational (revenue for EAA and SAMI), trial (Tigris and DIMI) and financing (Nasdaq listing and sale of minor stake in Dialco) targets have not been achieved with no reasons offered that can be understood by the shareholders. Normally one would expect that such abysmal performance would result in dismissal and not promotion.
So I think it's the board that owes the shareholders a rational explanation for their actions to promote rather than dismiss. They are the ones that should have solid reasons for their actions and should put forth their reasoning for such actions. That's the role of the board.
Bingo !
A Board doesn't sit idly by while 2/3 of the MCap is wiped out in a little over 6 months.
A clue is in your first , well sumarized paragrpah
"...
company has massive scientific achievements over a couple of years with the last two items (admittedly major ones) progressing very positively. This company has extended the time frame for use of technology agreements for PMX (Toray) and SAMI and DIMI (Infomed) and has a major pharma company on board with Baxter. They have the leading industry expert on board as the CMO. There is an investment analyst (Paradigm) with a valuation for the company well in excess of the current trading price. Everything is pointing to a once in a decade home run of biblical proportions..."
No amount of misspeaking (false promises) by the designated front man can justify a 2/3 MC hit. The assets are the assets and ST SP flucuations don;t change that. In fact, I contend that the value of said assets is ONLY GROWIING, from what I can determine. Likely, a dog with a note could bring this one home.
One thing is for sure, the Board knows full well the value of their assets especially once rubber stamped. Are they interested in having the value reflected prior to final approval?...clearly not.
This is zero % about the next 24 months revenues, Qtrly earnings, and some Trial delays, and 100% about the end-game, the denounement, and the all important, yet to be disclosed, value discovering event.
My suspicion is that the BoD memebers are looking at the SP and they are feeling one or more of the following:
- mildly amused
- suggesting that F&F advantage of the new lows
- happy that someone else is taking the short term heat as the master plan unfolds - pretty much as it should
- relishing the next Option grant
Regarding the average Joe retailer, the smart ones and gutsy ones in my group are: (1) ignoring the SH quibblers/FUD workers, and (2) holdling thier noses and adding whenever they can.
MM